Organogenesis achieves primary endpoint in diabetic foot ulcer trial
Go back to Organogenesis achieves primary endpoint in diabetic foot ulcer trial| (NASDAQ: ORGO) | Delayed: 2.39 -0.04 (1.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.43 | 52 Week High | $ | |||
| Open | $2.42 | 52 Week Low | $ | |||
| Day High | $2.45 | P/E | N/A | |||
| Day Low | $2.32 | EPS | $ | |||
| Volume | 189,059 | |||||
